Search results for "From ACP Journal Club"

Results 11 - 20 of about 131 for "From ACP Journal Club".

In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events | ACP Diabetes Monthly

The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.

DPP-4 inhibitors are less effective than metformin for reducing hemoglobin A1c | ACP Diabetes Monthly

A meta-analysis of randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin and other drugs found that DPP-4 monotherapy is less effective.

Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients | ACP Diabetes Monthly

More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.

Intensive weight management in primary care improved weight loss and remission of type 2 diabetes | ACP Diabetes Monthly

The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to

Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality | ACP Diabetes Monthly

The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.

Review: Intensive blood pressure control reduces retinopathy in diabetes | ACP Diabetes Monthly

Intensive control of blood pressure reduced incidence of retinopathy, but not progression of established retinopathy, in patients with type 1 or 2 diabetes, according to an analysis of 15 randomized controlled trials.

In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization | ACP Diabetes Monthly

If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.

Bariatric surgery improved HbA1c at 5 y more than intensive medical care alone in obese patients with T2DM | ACP Diabetes Monthly

A commentary considers the industry-funded STAMPEDE trial, in which obese patients with type 2 diabetes were randomly assigned to intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes | ACP Diabetes Monthly

A meta-analysis included 67 randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to placebo or other oral antidiabetic agents.

In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y | ACP Diabetes Monthly

A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next